| 品牌 | 貨號(hào) | 產(chǎn)品規(guī)格 | 價(jià)格(RMB) | 庫(kù)存（上海） | 北京 | 武漢 | 南京 | 購(gòu)買(mǎi)數(shù)量 |
|---|---|---|---|---|---|---|---|---|
| 源葉(MedMol) | S20672-5mg | 98% | ￥1000.00元 | 4 | - | - | - |
|
| 源葉(MedMol) | S20672-10mg | 98% | ￥1800.00元 | 5 | - | - | - |
|
| 源葉(MedMol) | S20672-25mg | 98% | ￥3600.00元 | 5 | - | - | - |
|
| 源葉(MedMol) | S20672-100mg | 98% | ￥9000.00元 | 預(yù)計(jì)交期：2-3天 | - | - | - |
|
Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
| 產(chǎn)品描述： | Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO). |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | TyrosineKinases | ||||||||||||||||||||
| 溶解性： | soluble in DMSO | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶(hù)參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號(hào)
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注上海源葉微信公眾號(hào)
北京